Beyond Ozempic: Why Silicon Valley Is Turning to Experimental Peptides
Jasmine Sun on unregulated peptides moving from fringe biohacking to Silicon Valley mainstream, promising healing, focus, and optimization with little oversight
More Videos
The Streaming Wars Just Got a Major Shake-Up
Kerry Flynn, Media Reporter at Axios, breaks down Fox's $22 billion acquisition of Roku and what it means for streaming, advertising, and viewers.
Kevin Warsh's First Fed Meeting Just Sent a Message to Wall Street
Bill Adams, Chief U.S. Economist at Fifth Third Bank, breaks down the Fed's latest decision, inflation risks, and what Kevin Warsh's debut means for markets.
After a Historic IPO, Can SpaceX Stock Keep Climbing?
Lou Whiteman, Contributing Aerospace Analyst at The Motley Fool, discusses SpaceX's volatile first week of trading and what investors should watch next.
The Great Income Shift: How Americans Are Building Wealth Beyond Their Day Jobs
Christine Kahm, Head of Customer Strategy & Intelligence at Block, shares insights into how Americans are building income beyond the 9-to-5.
The Colonel Gets a Glow-Up: Inside KFC's Massive Global Rebrand
KFC Chief Concept Officer Christophe Poirier joins us to discuss the brand's sweeping global rebrand, menu innovation, and vision for the future.
SpaceX IPO Shocks Wall Street: Is This the Biggest Investment of the Decade?
Keith Snyder, Senior Equity Analyst at CFRA, explains what's driving investor demand for SpaceX and whether the excitement is justified.
